Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mindfulness therapy tested to calm Parkinson's stress

NCT ID NCT05779137

Symptom relief Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether mindfulness-based cognitive therapy (MBCT) can reduce psychological distress in people with Parkinson's disease. 174 participants with mild-to-moderate stress symptoms will either receive MBCT or continue usual care. The main goal is to see if MBCT lowers anxiety and depression scores after the program.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mindfulness-based cognitive therapy
What this could lead to
If it works, this could offer a drug-free way to ease anxiety and depression in Parkinson's, and possibly slow disease progression.
What could go wrong
This is a mid-sized trial testing a behavioral intervention, not a drug. Results may be modest or not generalizable, and benefits may not last long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 174 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria for the RCT: * A diagnosis of idiopathic PD made by a movement disorders specialist. * PD disease duration is ≤10 years, defined as time since diagnosis made by a neurologist. * Mild-moderate symptoms of psychological distress (Hospital Anxiety and Depression Scale score \>10 points). * Subject can read and understand the Dutch language. Exclusion criteria for the RCT: * Severe neurological or psychiatric co-morbidity (e.g. psychosis or suicidality). * Contraindications for MRI (e.g. brain surgery in medical history, claustrophobia, an active implant, epilepsy, pregnancy, and/or metal objects in the upper body that are incompatible with MRI). * Moderate to severe head tremor (to avoid artifacts caused by extensive head motion during scanning). * Cognitive dysfunction (clinical diagnosis of dementia, or a score of 20 or lower on the MoCA, which will be measured at T0). * Previous participation in MBSR or MBCT (\>4 sessions). Inclusion criteria (HC group): • Participants of the HC group must be able to read and understand the Dutch language. Exclusion criteria (HC group): * Severe neurological or psychiatric co-morbidity (e.g. psychosis or suicidality). * Contraindications for MRI (e.g. brain surgery in medical history, claustrophobia, an active implant, epilepsy, pregnancy, and/or metal objects in the upper body that are incompatible with MRI). * Cognitive dysfunction (clinical diagnosis of dementia, or a score of 20 or lower on the MoCA, which will be measured at T0). * Detailed knowledge about the nature of the stress induction paradigm prior to participating in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Disease Progression Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson's disease

Contacts and locations

Locations

  • Donders Centre for Cognitive Neuroimaging

    Nijmegen, 6525 EN, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.